Cardiovascular risk and the COVID-19 pandemic: a population-based and case‒control studies

Table 2 Characteristics of the studied populations and comparison variables between them: general data, laboratory tests

Variable	Group I N = 691	Group II N = 816	P	Group III N = 126	Control group IV N = 126	P
Age, years	48.7 ± 15.4	49.3 ± 15.3	0.460	56.6 ± 12.5	58.5 ± 11.7	0.211
Male sex, n (%)	310 (44.9)	377 (44.9)	0.603	61 (48.4)	61 (48.4)	1.0
BPs, mmHg	124.9 ± 17.7	122.4 ± 17.3	0.006	127.0 ± 17.3	130.9 ± 19.2	0.096
BPd, mmHg	81.7 ± 10.1	79.8 ± 10.0	< 0.001	82.3 ± 10.6	84.7 ± 10.5	0.071
HR, bpm	71.8 ± 10.7	71.5 ± 10.7	0.594	68.8 ± 9.6	71.1 ± 10.3	0.065
Fasting glucose, mg/dL	103.5 ± 20.6	103.0 ± 18.4	0.178	106.5 ± 26.4	111.4 ± 20.6	0.102
OGTT 120 min glucose, mg/dL	125.2 ± 38.5	124.2 ± 36.8	0.145	-	-	-
HbA1c, %	5.5 ± 0.6	5.5 ± 0.6	0.520	5.6 ± 0.8	5.8 ± 0.6	0.073
TC, mg/dL	191.3 ± 41.4	192.6 ± 41.5	0.562	192.8 ± 45.6	195.3 ± 44.0	0.657
LDL-c, mg/dL	125.3 ± 37.5	120.3 ± 37.1	0.010	119.3 ± 40.0	130.5 ± 40.2	0.028
HDL-c, mg/dL	63.0 ± 17.2	60.0 ± 16.3	0.001	57.4 ± 15.2	59.0 ± 16.8	0.419
TG, mg/dL	112.7 ± 70.9	115.5 ± 82.4	0.471	128.2 ± 70.6	132.5 ± 66.4	0.615
Creatinine, µmol/L	69.1 ± 13.5	72.7 ± 25.8	0.001	81.4 ± 92.0	71.1 ± 13.1	0.215
eGFR, mL/min/1.73m²	101.3 ± 29.1	96.6 ± 21.4	0.001	93.2 ± 24.9	93.8 ± 18.4	0.627
ACR mg/g	7.3 ± 19.5	8.0 ± 13.0	0.427	11.3 ± 22.1	7.6 ± 17.4	0.136

The data is shown as n (%) or mean (SD). ACR, albumin/creatinine ratio; BP, blood pressure; BPd, diastolic blood pressure; BPs, systolic blood pressure; bpm, beats per min; eGFR, estimated glomerular filtration rate; HbA1 c, hemoglobin A1 c; HDL-c, high-density lipoprotein; HOMA-IR, homeostasis model assessment of insulin resistance; HR, heart rate; LDL-c, low-density lipoprotein; mmHg, millimetres of mercury; OGTT, oral glucose tolerance test; SD, standard deviation; TC, total cholesterol; TG, triglycerides

ISSN: 1478-7954